Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With

To study whether This open-label, histology-independent, phase II study included six prespecified cohorts, including patients with NSCLC, and a seventh all-comers cohort. Patients received vemurafenib (960 mg two times per day) until disease progression or unacceptable toxicity. The primary end point of the final analysis was objective response rate (Response Evaluation Criteria in Solid Tumors, version 1.1). Secondary end points included progression-free survival, overall survival, and safety. Because the prespecified clinical benefit endpoint was met in the initial NSCLC cohort, the cohort was expanded. Sixty-two patients with Vemurafenib showed promising activity in patients with NSCLC harboring

Informations de copyright

© 2019 by American Society of Clinical Oncology.

Déclaration de conflit d'intérêts

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Vivek SubbiahConsulting or Advisory Role: MedImmune Research Funding: Novartis (Inst), GlaxoSmithKline (Inst), NanoCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech (Inst), Berg Pharma (Inst), Bayer (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), Amgen (Inst), AbbVie (Inst), Multivir (Inst), Blueprint Medicines (Inst), Loxo (Inst), Vegenics (Inst), Takeda (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Biomedical (Inst), Inhibrx (Inst), Exelixis (Inst) Travel, Accommodations, Expenses: PharmaMar Expenses: BayerGregory RielyResearch Funding: Novartis (Inst), Genentech (Inst), Millennium (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Infinity Pharmaceuticals (Inst), Ariad (Inst), Mirati Therapeutics (Inst), Merck (Inst) Patents, Royalties, Other Intellectual Property: Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst) Travel, Accommodations, Expenses: Merck Sharp & Dohme Other Relationship: Pfizer, Genentech, TakedaAntoine HollebecqueHonoraria: Merck Serono Consulting or Advisory Role: Amgen, AstraZeneca/MedImmune (Inst), Gritstone Oncology, Incyte (Inst), Eli Lilly (Inst), Spectrum Pharmaceuticals (Inst) Travel, Accommodations, Expenses: Amgen, Servier, Eli Lilly, AstraZeneca/MedImmune Other Relationship: AbbVie, Agios, Amgen, Argenx, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharma, Clovis Oncology, Daiichi Sankyo, Debiopharm Group, Eisai, Exelixis, Forma Therapeutics, GamaMabs Pharma, Genentech, GlaxoSmithKline, H3 Biomedicine, Innate Pharma, Janssen-Cilag, Kyowa Hakko Kirin, Loxo, Lytix Biopharma, MedImmune, Menarini, Merck Sharp & Dohme, Merrimack, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar, Novartis, Octimet, Oncoethix, Onyx, Orion Pharma, Oryzon Genomics, Pfizer, Pierre Fabre, Genentech, Sanofi/Aventis, Taiho Pharmaceutical, Tesaro, Xencor, Roche, Servier, Eli LillyJean-Yves BlayLeadership: Innate Pharma Honoraria: Roche, Novartis Bayer, GlaxoSmithKline, Pharmamar, Eli Lilly Consulting or Advisory Role: Roche, Novartis, GlaxoSmithKline, Bayer, PharmaMar, Merck, GlaxoSmithKline (Inst), PharmaMar (Inst), Novartis (Inst), Bayer (Inst), Roche (Inst) Other Relationship: Innate PharmaEnriqueta FelipConsulting or Advisory Role: Pfizer, Roche, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Celgene, Guardant Health, Novartis, Takeda, AbbVie, Blueprint Medicines, Eli Lilly, Merck, Merck Sharp & Dohme Speakers' Bureau: AstraZeneca, Bristol-Myers Squibb, Novartis, Boehringer Ingelheim, Merck Sharp & Dohme, Roche, Pfizer, AbbVie, Eli Lilly, Merck, Takeda Research Funding: Fundación Merck Salud (Inst), EMD Serono (Inst)Martin SchulerHonoraria: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Eli Lilly, Celgene Consulting or Advisory Role: AstraZeneca Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Roche Research Funding: Bristol-Myers Squibb (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), AstraZeneca (Inst) Patents, Royalties, Other Intellectual Property: Highly sensitive method for mutation detection by polymerase chain reaction (Inst)Anthony GonçalvesResearch Funding: MSD (Inst), Bristol-Myers Squibb (Inst), Novartis (Inst), Cascadian Therapeutics (Inst), Nektar (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), AbbVie (Inst), Genentech (Inst), AstraZeneca (Inst), Roche (Inst) Travel, Accommodations, Expenses: Pfizer, Novartis, Genentech, Celgene, Boehringer Ingelheim, MSD, AstraZenecaAntonio ItalianoHonoraria: Bayer, Daiichi Sankyo, Eli Lilly, Epizyme, Novartis, Roche Consulting or Advisory Role: Roche, Daiichi Sankyo, Immune Design, Epizyme, Bayer, Eli Lilly Research Funding: Roche, Bayer, AstraZeneca/MedImmune, PharmaMar, MSD Oncology, Merck Serono, Merck SeronoVicki KeedyConsulting or Advisory Role: Karyopharm Therapeutics Research Funding: Medpacto (Inst), Plexxikon (Inst), Roche (Inst), Daiichi Sankyo (Inst), Eli Lilly (Inst), BioMed Valley Discoveries (Inst), Immune Design (Inst), GlaxoSmithKline (Inst), Tracon Pharma (Inst), Advenchen Laboratories (Inst)Ian ChauHonoraria: Eli Lilly Consulting or Advisory Role: Eli Lilly, Bristol-Myers Squibb, MSD Oncology, Merck Serono, Genentech, Bayer, AstraZeneca, Oncologie International, Pierre Fabre Research Funding: Janssen-Cilag (Inst), Sanofi (Inst), Merck Serono (Inst), Eli Lilly (Inst) Travel, Accommodations, Expenses: MSD, Merck Serono, Eli Lilly, Bristol-Myers SquibbIgor PuzanovConsulting or Advisory Role: Amgen, Genentech, Bristol-Myers Squibb Travel, Accommodations, Expenses: Amgen, MerckNoopur S. RajeConsulting or Advisory Role: Amgen, Celgene, Takeda, Novartis, Bristol-Myers Squibb, Merck, Janssen Oncology Research Funding: AstraZeneca (Inst)Funda Meric-BernstamHonoraria: Sumitomo Group, Dialectica Consulting or Advisory Role: Genentech, Inflection Biosciences, Pieris Pharmaceuticals, Clearlight Diagnostics, Darwin Health, Samsung Bioepis, Spectrum Pharmaceuticals, Aduro Biotech, Origimed, Xencor, Debiopharm Group, Mersana Research Funding: Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, Bayer, Aileron Therapeutics, Puma Biotechnology, CytomX Therapeutics, Jounce Therapeutics, Zymeworks, Curis, Pfizer, Effector Therapeutics, AbbVie, Boehringer Ingelheim (I), Guardant Health (Inst), Daiichi Sankyo, GlaxoSmithKlineMartina MakrutzkiEmployment: RocheTodd RiehlEmployment: Genentech Stock and Other Ownership Interests: GenentechBethany PitcherEmployment: Hoffmann-La RocheJose BaselgaLeadership: Infinity Pharmaceuticals, Varian Medical Systems, Bristol-Myers Squibb, Foghorn Stock and Other Ownership Interests: PMV Pharma, Juno Therapeutics, Grail, Tango, Venthera, Northern Biologics, Apogen Biotechnologies, Aura Biosciences Consulting or Advisory Role: Novartis Patents, Royalties, Other Intellectual Property: Combination therapy using PDK1 and PI3K inhibitors, use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations, inhibition of KMT2D for the treatment of cancer Travel, Accommodations, Expenses: Roche, Daiichi SankyoDavid M. HymanConsulting or Advisory Role: Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Genentech Research Funding: AstraZeneca, Puma Biotechnology, Loxo, Bayer Travel, Accommodations, Expenses: Genentech, Chugai Pharma No other potential conflicts of interest were reported.